To monitor the effects of the treatment, PET/CT scans, which are specialized imaging tests that show how the body uses certain substances, will be used to look at the state of the arteries. These scans help track changes in inflammation levels within the carotid arteries, which are the main blood vessels located in the neck. The process involves comparing the level of inflammation at the beginning of the study to the level measured after six months of treatment.

The purpose of this research is to find out which medication works fastest to lower heart rate in patients whose resting heart rate is above 65 beats per minute. The medications will be given by mouth, with different maximum daily doses: ivabradine up to 15 mg, atenolol up to 100 mg, and metoprolol succinate up to 200 mg.

During the study, patients will receive one of these medications before their cardiac CT scan. The heart rate will be monitored to see how quickly it decreases after taking the medication. A cardiac CT scan is a specialized X-ray examination that provides detailed images of the heart and blood vessels.

During the trial, participants will receive Adenosine through an intravenous infusion, which means the medication will be delivered directly into the bloodstream through a vein. Another medication, Gadoteric Acid, may be used as a contrast agent to help visualize the heart’s blood flow during imaging tests. The main goal of the study is to understand how different doses of Adenosine affect the heart’s blood flow, which will be measured using a special imaging technique called CMR (Cardiac Magnetic Resonance) imaging.

The trial aims to provide valuable insights into the treatment of Chronic Coronary Syndrome by determining the most effective dose of Adenosine for improving heart blood flow. This information could help doctors make better decisions about how to use Adenosine in patients with this heart condition. The study is expected to continue until 2026, with recruitment of participants starting in 2024.

The purpose of the study is to explore how blood vessel growth in the heart changes before and after a procedure to restore blood flow, known as coronary revascularization. Participants will undergo imaging with RGD-PET both before and after this procedure. The study will also look at how these changes relate to heart function and recovery over time.

Throughout the study, participants will have several imaging sessions to monitor changes in their heart’s blood vessels and function. The study aims to provide a better understanding of how the heart heals and adapts after treatment for chronic ischemic heart disease, potentially leading to improved care for patients with this condition.

Participants in the study will be randomly assigned to receive either Ivabradine or a placebo, which is a substance with no active medication. The study will monitor the participants for any signs of heart injury, such as a heart attack or elevated levels of a heart-related protein called cardiac troponin, within 30 days after their surgery. The trial will also look at other outcomes, such as the occurrence of stroke, heart-related death, and overall health and recovery after surgery.

The study will take place over a period of time, with participants being observed for any changes in their health related to the surgery and the medication. The goal is to determine if Ivabradine can effectively prevent heart injury in patients undergoing non-heart-related surgeries, potentially improving their recovery and overall health outcomes.

The purpose of the study is to investigate whether these treatments can help reduce the buildup of fatty deposits, known as atherosclerotic plaques, in the arteries of the heart. Participants will receive either psilocybin-assisted psychotherapy or midazolam-assisted psychotherapy. The study will last for 12 months, during which participants will undergo regular heart examinations to monitor changes in plaque volume. The researchers hope to see a reduction in plaque volume, which could improve heart health.

Throughout the study, participants will be monitored using various techniques, including Optical Coherence Tomography (OCT), a method that provides detailed images of the heart’s arteries. The study aims to understand how these treatments might influence the composition of the plaques and potentially reduce the risk of heart-related complications. By the end of the study, the researchers hope to gather valuable information on the effectiveness of these treatments in managing ischemic heart disease.

The purpose of the study is to see if Colchicine can improve blood flow in the heart and reduce symptoms in patients with CMD. The study will last for about six months. During this time, participants will undergo various assessments, including heart scans, to measure changes in blood flow and symptom questionnaires to evaluate any changes in their angina symptoms. The study will also look at how Colchicine affects certain proteins and functions in the blood vessels.

In addition to Colchicine, the study will involve the use of Regadenoson and Adenosine, which are substances used to stress the heart during certain tests, and local anesthetics, which are used to numb specific areas of the body. These substances will help researchers better understand the effects of Colchicine on heart function and blood flow. The study aims to provide valuable insights into potential new treatments for CMD and improve the quality of life for those affected by this condition.

The purpose of the study is to assess the outcomes of patients 30 days after receiving the treatment. Participants will receive a single injection of Zalunfiban or a placebo before they reach the hospital. The study will monitor the patients for any major health events, such as death, stroke, or another heart attack, as well as any bleeding incidents, which are important safety concerns. The study aims to provide insights into how Zalunfiban might help improve the condition of patients with STEMI when administered early.

Throughout the study, patients will be observed for any side effects or reactions at the injection site. The trial will also track the patients’ recovery and any additional treatments they might need. This research is important for understanding how Zalunfiban can be used to potentially improve outcomes for people experiencing a heart attack, offering new possibilities for treatment in emergency situations.

The purpose of the study is to see if these medications can help reduce the risk of complications, shorten the length of hospital stay, and improve overall recovery after heart surgery. Participants will receive either the medication or a placebo, which looks like the medication but does not contain any active ingredients. The study will also look at different ways to manage blood flow and breathing during surgery to see if these methods can further improve recovery.

Throughout the study, participants will be monitored for up to 90 days after their surgery to track their recovery progress. The main focus will be on how many days they are alive and outside the hospital during this period. The study will also look at other important outcomes, such as survival rates, the occurrence of complications like stroke or kidney injury, and overall quality of life after surgery. This research aims to find the best ways to support patients’ recovery and improve their health outcomes after heart surgery.